Table 3:
Multivariable analysis* of developing glucose intolerance by day +30 by BMI-derived categories
| Non-overweight | ||||
|---|---|---|---|---|
| HR | 95% CI | P-value | ||
| Diagnosis | AML, ALL, other | 1.00 | -- | -- |
| MDS | 3.32 | 1.14-9.69 | 0.029 | |
| Abnormal SMG | No | 1.00 | -- | -- |
| Yes | 3.00 | 1.15-7.81 | 0.024 | |
| Overweight/obese | ||||
| HR | 95% CI | P-value | ||
| Ethnicity | Non-Hispanic | 1.00 | -- | -- |
| Hispanic | 2.27 | 1.25-4.11 | 0.007 | |
| VAT | Normal | 1.00 | -- | -- |
| Abnormal | 2.26 | 1.24-4.11 | 0.008 | |
| GVHD by day +30 | No | 1.00 | -- | -- |
| Yes | 1.96 | 1.08-3.55 | 0.027 | |
*
Models were adjusted for BMI (continuous variable)
BMI= body mass index; HR= hazard ratio; CI= confidence interval; AML= acute myeloid leukemia; ALL= acute lymphoblastic leukemia; MDS= myelodysplastic syndrome; SMG= skeletal muscle gauge; VAT= visceral adipose tissue; GVHD= graft-versus-host disease